Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of endogenous GIP in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mechanisms in Endocrinology: FXR signalling - a novel target in metabolic diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of β-hydroxybutyrate on cognition in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Antidiabetic medication and risk of dementia in patients with type 2 diabetes. A nested case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucagon Clearance is Preserved in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exendin(9-39)NH2 - recommendations for clinical use based on a systematic literature review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Mads R Andersen
  • Malte P Suppli
  • Jonatan I Bagger
  • Mikkel B Christensen
  • Gina L C Yosten
  • Filip K Knop
  • Asger Lund
Vis graf over relationer

In 2008, the first evidence of a new hormone called neuronostatin was published. The hormone was discovered using a bioinformatic method and found to originate from the same preprohormone as somatostatin. This small peptide hormone of 13 amino acids and a C-terminal amidation was soon found to exert pleiotropic physiological effects. In animal studies, neuronostatin has been shown to reduce food intake and delay gastric emptying and gastrointestinal transit. Furthermore, neuronostatin has been shown to affect glucose metabolism by increasing glucagon secretion during situations when glucose concentrations are low. Additionally, neuronostatin has been shown to affect neural tissue and cardiomyocytes by suppressing cardiac contractility. The effects of neuronostatin have not yet been delineated in humans, but if the effects found in animal studies translate to humans it could position neuronostatin as a promising target in the treatment of obesity, hypertension and diabetes. In this review, we describe the discovery of neuronostatin and the current understanding of its physiological role and potential therapeutic applicability.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind185
Udgave nummer4
Sider (fra-til)R93-R101
ISSN0804-4643
DOI
StatusUdgivet - 1 sep. 2021

ID: 67568344